The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Change in CM-specific Immunoglobulin G4 (IgG4)
研究概览
简要总结
The purpose of this study is to determine if small oral and sublingual doses of milk protein are safe and effective in decreasing sensitivity to cow's milk in allergic children.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Are age 6 to 21 years
- •Provide signed informed consent (by parent or legal guardian if the subject is a minor), and informed assent if applicable
- •Have a history of symptomatic reactivity to cow's milk (i.e. Eczema, urticaria, upper or lower respiratory symptoms, GI disturbances, other rash or oral symptoms)
- •Have a positive skin prick test (defined as wheal 3 mm ≥ negative control) and cow's milk- immunoglobulin E (IgE) > 0.35 kilo Immunoglobulin Units (kIU)/L
- •Have a positive OFC to cow's milk at a cumulative dose of less than 184 milligrams of cow's milk intact protein (2,400 mg total milk protein).
- •Are using appropriate birth control if subject is female and of child bearing age.
- •Have self-injectable epinephrine (ie. EpiPen® or EpiPen Jr.®) available at home
排除标准
- •Have a history of severe anaphylaxis defined as hypoxia (cyanosis or SpO2 ≤ 92% at any stage), hypotension, confusion, collapse, loss of consciousness; or incontinence
- •Have a history of intubation related to asthma
- •Tolerate more than 184 milligrams of intact cow's milk protein at initial OFC
- •Are pregnant or lactating
- •Have a viral Upper Respiratory Infection (URI) or gastroenteritis within 7 days of OFC (OFC needs to be rescheduled)
- •Have pulmonary function tests <80% of predicted (FEV1) or clinical history consistent with more than moderate persistent asthma
- •Are currently taking greater than medium dose inhaled corticosteroid (>400 mcg/day fluticasone or fluticasone equivalent if ≤ 12 years old or > 600 mcg/day if > 12 years old)
- •Are unable to discontinue antihistamines for 5 days for long acting and 3 days for short acting prior to skin testing or food challenges
- •Have used systemic corticosteroids within 4 weeks prior to baseline visit
- •Are receiving omalizumab, beta-blocker, Angiotensin Converting Enzyome (ACE) inhibitor or tricyclic antidepressant therapy
- •Have a chronic disease (other than asthma, atopic dermatitis or rhinitis) requiring therapy (e.g., heart disease, diabetes)
- •Have participated in any interventional study for treatment of a food allergy in the past 12 months
- •Have a severe reaction at initial DBPCFC, defined as either:
- •Life-threatening anaphylaxis, or Reaction requiring hospitalization
研究组 & 干预措施
Sublingual Immunotherapy (SLIT)
These subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year.
Milk Protein Extract Immunotherapy : Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
干预措施: Milk Protein Extract Immunotherapy goal of 4mg/day (Drug)
Sublingual Immunotherapy (SLIT)
These subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year.
Milk Protein Extract Immunotherapy : Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
干预措施: Milk Protein Extract Immunotherapy goal of 7mg/day (Drug)
SLIT/ Oral Immunotherpay (OIT) B
These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.
Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
干预措施: Milk Protein Extract Immunotherapy goal of 4mg/day (Drug)
SLIT/ Oral Immunotherpay (OIT) B
These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.
Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
干预措施: Milk Powder Immunotherapy goal dose 1000mg/day (Drug)
SLIT/ OIT A
These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.
Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
Milk Protein Extract Immunotherapy : Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
干预措施: Milk Protein Extract Immunotherapy goal of 4mg/day (Drug)
SLIT/ OIT A
These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.
Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
Milk Protein Extract Immunotherapy : Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
干预措施: Milk Powder Immunotherapy goal dose 2000 mg/day (Drug)
结局指标
主要结局
Change in CM-specific Immunoglobulin G4 (IgG4)
时间窗: Change from baseline to after therapy (up to 18 months)
Cow's milk specific IgG4 was measured at baseline and after therapy (kUa/L)
Change in End Point Skin Test
时间窗: Change from baseline to after therapy (up to 18 months)
Allergen provoked skin test (mm)
Change in CM-specific Immunogloblin E (IgE)
时间窗: Change from baseline to after therapy (up to 18 months)
Cow's milk specific IgE was measured at baseline and after therapy (kUa/L)
Oral Food Challenge Threshold (OFC) Threshold
时间窗: Change from baseline to after therapy (up to 18 months)
mg CM protein
次要结局
未报告次要终点